Clinical Surgical Oncology’s Post

🌟 Publication highlight! 🌟 "Predictors of Early Recurrence of Oesophagogastric Adenocarcinoma After Neoadjuvant FLOT" Despite advancements in treatment, recurrence rates for oesophagogastric adenocarcinoma remain high, particularly following curative surgery. A new study by Abbienaya Dayanamby et al. dives into predictors of early recurrence in patients treated with neoadjuvant FLOT chemotherapy. 🔍 Key Findings: - 27.6% of patients experienced recurrence during follow-up, with 13.8% having early recurrence - Median survival after recurrence is 4.1 months - Independent risk factors for ER include extracapsular spread and ypN3 stage Understanding these predictors enables tailored follow-up strategies, such as more frequent imaging and targeted treatments for high-risk patients. Read the full article here: https://lnkd.in/dueek_3k Read the latest issue here: https://lnkd.in/eZH3ZNFZ Riccardo A. Audisio, Andreas Karakatsanis, Isacco Montroni Graeme Poston, John Whiting, Hassan Malik, Maggie Banys-Paluchowski, Marios Konstantinos Tasoulis MD, PhD, FEBS, FRCS, FACS, Pasithorn Suwanabol, harm rutten, Albert Wolthuis, Prof. dr. Barbara van Leeuwen, Giorgio Bogani, Volkert Wreesmann, Roberto Biffi, Nicola de' Liguori Carino, Roger Bagge Olofsson, Rachel Grossman, Olivier Glehen, Sylvie Bonvalot, Michael Shackcloth, Young-Woo Kim, Franco Roviello, Brian Birch, Pietro Mascagni, Denise Hilling, Dawn Aggett European Society of Surgical Oncology (ESSO), BASO ACS Abbienaya Dayanamby, Jakub Chmelo, Alexander Bradshaw, Alexander Phillips #CancerResearch #Oncology #Oesophaguscancer #EarlyRecurrence

The prevalence of preoperative anemia is the highest in the group of colorectal cancer (CRC) patients and may reach over 75%. The prevalence of anemia in CRC patients increases even further following surgery. Approximately 75–80% of anemic CRC patients present with absolute or functional iron deficiency. Preoperative anemia constitutes an independent risk factor for allogeneic blood transfusion (ABT), postoperative complications, prolonged length of hospital stay, and increased mortality. ABT is itself associated with increased morbidity and mortality. We present a review article on this very important topic.

🌟 Feasibility of Upfront Surgery in Resectable Gastric Cancer with Outlet Obstruction 🌟 Can upfront radical surgery redefine the approach to gastric cancer with gastric outlet obstruction (GOO)? A recent study involving 52 patients suggests it can - ✅ 100% R0 resection achieved ✅ Post-operative morbidity: 32.7% but no mortality ✅ 📈2-year overall survival (OS): 59.3% ✅ 78.8% completion rate of adjuvant chemotherapy Key Findings: 🩺 Complication Rates: Gastroparesis (19.2%) was the most common issue, successfully managed conservatively. 📊 Survival Factors: Non-completion of adjuvant chemotherapy (HR 2.68, p = 0.038) and poor tumor differentiation (HR 2.77, p = 0.015) were linked to worse outcomes. 🔄 Recurrence: 42.3% of cases experienced recurrence, primarily peritoneal (59.1%). This study highlights the importance of pre-operative optimization (nutrition, physiotherapy) and a multimodal approach, demonstrating that upfront surgery is a viable and potentially curative option for resectable GOO cases. #Oncology #SurgicalOncology #GastricCancer IASO-IJSO online update https://lnkd.in/gNwtyZ78

💉 While #chemotherapy has been the treatment of choice for #gastriccancer, the use of cytoreductive surgery is on the rise, especially in combination with hyperthermic intraperitoneal chemotherapy. 👇 Read more about this combination and how it can offer better PFS for patients:

The study included 1,600 women with early breast cancer who were planned to be treated with surgery. Half of these patients, constituting the control group, received standard surgery followed by standard post-operative treatment including chemotherapy, hormone therapy and radiotherapy as per guidelines. The other half, constituting the intervention group, received an injection of a commonly used local anaesthesia agent, 0.5% lidocaine, all around the tumor, just prior to surgery. They then underwent standard surgery followed by the same postoperative treatment as was given in the control group. The results of this study show that this simple, low-cost intervention significantly and substantially increases the cure rates and survival of breast cancer patients, with a benefit that is ongoing for several years after surgery. The injection requires no additional expertise, is inexpensive, and can result in saving up to 100,000 lives annually globally. These benefits are substantial and were achieved with an intervention the cost of which was less than Rs.100/- per patient. For comparison, benefits of far lesser magnitude have been achieved in early breast cancer patients by much more expensive, targeted drugs which cost more than ten lakhs per patient. The clinical trial is hence an important milestone in the treatment of breast cancer.

Check out my latest article on the #ovarian causes of #Pseudomyxoma Peritonei https://lnkd.in/dKe_e4J6 #gynonc #gynecooncology #oncology #gyneoncology #gynecancers #review #healtheducation #surgery #cancer #womenshealth #medicine #HIPEC #cytoreductive

Online!🌍 #Colorectalcarcinoma peritoneal metastases-derived #organoids: results and perspective of a model for tailoring hyperthermic intraperitoneal #chemotherapy from bench-to-bedside ---------------- Peritoneal metastases from colorectal cancer (CRCPM) are related to poor prognosis. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been reported to improve survival, but peritoneal recurrence rates are still high and there is no consensus on the drug of choice for HIPEC. The aim of this study by Dr. Marcello Deraco et al. was to use patient derived organoids (PDO) to build a relevant CRCPM model to improve HIPEC efficacy in a comprehensive bench-to-bedside strategy. Open access👇 https://lnkd.in/dFakXzuu #Personalizedmedicine IFO - Istituto Nazionale Tumori Regina Elena - Istituto Dermatologico San Gallicano

Intra-abdominal collections after CRS and HIPEC can be a challenge to manage but percutanous drainage by interventional radiology may avoid a laparotomy European Society of Surgical Oncology (ESSO) Peritoneal Surface Oncology Group International (PSOGI) https://lnkd.in/eH2xdBVC

'At this first prespecified interim analysis, adjuvant pembrolizumab, as compared with observation, was associated with a significant lengthening of disease-free survival in patients with high-risk muscle-invasive urothelial carcinoma after radical surgery.' #Immunology #Immunotherapy  https://lnkd.in/d8Huc46T

Neoadjuvant chemotherapy before breast conserving surgery may not be necessary for T2N0-1M0 HR-positive/HER2-negative BC patients. At The London Breast Institute, we recommend NAC only for specific cases where downsizing for BCS or axillary downstaging to avoid ALND is required, especially for young patients with grade 3 tumors and high Ki67. #BreastCancer #NeoadjuvantChemotherapy #BreastConservingSurgery #LondonBreastInstitute